303 related articles for article (PubMed ID: 25103842)
1. [Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy].
Holzer K
Chirurg; 2014 Aug; 85(8):731-44. PubMed ID: 25103842
[TBL] [Abstract][Full Text] [Related]
2. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
[TBL] [Abstract][Full Text] [Related]
3. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
4. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
6. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
[TBL] [Abstract][Full Text] [Related]
7. Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.
Tamagno G; Sheahan K; Skehan SJ; Geoghegan JG; Fennelly D; Collins CD; Maguire D; Traynor O; Brophy DP; Cantwell C; Swan N; McGowan L; O'Toole D; O'Shea D
Endocrine; 2013 Oct; 44(2):504-9. PubMed ID: 23471696
[TBL] [Abstract][Full Text] [Related]
8. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
[TBL] [Abstract][Full Text] [Related]
11. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors.
Du S; Ni J; Weng L; Ma F; Li S; Wang W; Sang X; Lu X; Zhong S; Mao Y
Medicine (Baltimore); 2015 Aug; 94(34):e1429. PubMed ID: 26313798
[TBL] [Abstract][Full Text] [Related]
12. [Gastroenteropancreatic neuroendocrine tumors : (GEP-NENs)].
Sebesta C; Feichter A; Selimi F
Wien Med Wochenschr; 2023 Jun; 173(9-10):221-226. PubMed ID: 36512264
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
Perez K; Chan J
Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
[TBL] [Abstract][Full Text] [Related]
14. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
de Herder WW
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):689-90. PubMed ID: 23582912
[No Abstract] [Full Text] [Related]
15. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation.
Niederle MB; Niederle B
Oncologist; 2011; 16(5):602-13. PubMed ID: 21467149
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia.
Ptasnuka M; Ozolins A; Narbuts Z; Truskovs A; Sperga M; Plaudis H
World J Surg; 2020 Feb; 44(2):585-593. PubMed ID: 31605174
[TBL] [Abstract][Full Text] [Related]
18. Gastroenteropancreatic Neuroendocrine Tumors.
Fernandes CJ; Leung G; Eads JR; Katona BW
Gastroenterol Clin North Am; 2022 Sep; 51(3):625-647. PubMed ID: 36153114
[TBL] [Abstract][Full Text] [Related]
19. [The diagnosis and treatment of G3 neuroendocrine tumors according to the new NCCN guideline].
Liang Y; Yu XJ; Chen J
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):982-987. PubMed ID: 35399015
[TBL] [Abstract][Full Text] [Related]
20. Highlights in GEP-NETs From the 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease: Commentary.
Iyer R; Hatoum H
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):17-9. PubMed ID: 27168109
[No Abstract] [Full Text] [Related]
[Next] [New Search]
